Key statistics dashboard for Oragenics, Inc. (OGEN). Valuation multiples (P/E, P/B, EV/EBITDA), profitability margins, financial-health ratios, per-share metrics and stock-level data in one consolidated view — the snapshot quantitative analysts and value investors check first.
Oragenics, Inc. (OGEN) is a U.S.-based biotechnology firm primarily focused on creating treatments for infectious diseases. Among its pipeline assets are two vaccine candidates designed to combat the novel severe acute respiratory syndrome coronavirus (SARS-CoV-2): NT-CoV2-1, an intranasal formulation, and Terra CoV-2, an intramuscular option.
Stock Data
| Price | $0.50 |
| Market Cap | $2M |
| Beta | 1.21 |
| Exchange | AMEX |
| Country | US |
Valuation Multiples
| P/E Ratio | -0.14 |
| Price / Book | 0.59 |
| P/S | 0.00 |
| P/FCF | -0.22 |
| Dividend Yield | 0.00% |
Profitability
| Gross Margin | 0.00% |
| EBIT Margin | 0.00% |
| EBITDA Margin | 0.00% |
| Operating Margin | 0.00% |
| Net Margin | 0.00% |
Financial Health
| Current Ratio | 3.01 |
| Quick Ratio | 3.01 |
| Cash Ratio | 2.12 |
| Debt / Equity | 0.00 |
| Debt / Assets | 0.00% |
| Interest Coverage | -561.90 |
Per-Share Data
| Revenue per share | 0.00 |
| Book Value per share | 0.83 |
| Cash per share | 0.87 |
| FCF per share | -2.30 |
| Tangible Book Value per share | 0.83 |
| Dividend per share | 0.00 |
Related companies: AIM · CANF · CNSP · ENSC · KALA · KZIA · QLGN
Explore sector: Healthcare · Biotechnology
More sections of OGEN: Overview · Financials · Valuation · Estimates · Technical · Ownership · News · Events
Discover more: Radar — undervalued stock signals · Investment Academy — learn to analyze stocks